Morningstar

BioMarin Pharmaceutical Inc BMRN

Stock XNAS Rating as of Nov 10, 2026

News

BioMarin to Participate in Upcoming Investor Conferences
PR Newswire Nov 4, 2026, 2:00:00 PM
BioMarin Reports Third Quarter 2026 Financial and Operating Results
PR Newswire Nov 2, 2026, 9:03:00 PM
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
PR Newswire Oct 29, 2026, 12:45:00 PM
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
PR Newswire Oct 26, 2026, 1:00:00 PM
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
PR Newswire Oct 9, 2026, 1:05:00 PM
BioMarin Appoints Cara Bauer as Chief People Officer
PR Newswire Oct 5, 2026, 8:05:00 PM
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
PR Newswire Oct 2, 2026, 3:00:00 PM
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
PR Newswire Sep 14, 2026, 1:05:00 PM
BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
PR Newswire Sep 9, 2026, 1:05:00 PM
BioMarin to Participate in Upcoming Investor Conferences
PR Newswire Sep 2, 2026, 1:00:00 PM
BioMarin Announces Close of the Alesta Therapeutics Acquisition
PR Newswire Sep 1, 2026, 1:05:00 PM
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
PR Newswire Aug 31, 2026, 6:00:00 AM
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
PR Newswire Aug 18, 2026, 12:30:00 PM

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2026 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.